MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Friedreich Ataxia. According to GlobalData, Phase II drugs for Friedreich Ataxia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MIB-626 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MIB-626 is under development for the treatment of Friedreich’s ataxia (FA), coronavirus disease 2019 (COVID-19), acute renal failure (ARF) (acute kidney injury), mild dementia and Leber’s hereditary optic neuropathy. The drug candidate is a crystallized precursor of nicotinamide adenine dinucleotide (NAD+). It is administered through oral route.
It was also under development for the treatment of muscle endurance (musculoskeletal disorders) and mitochondrial myopathy.
Metro International Biotech overview
Metro International Biotech is a clinical-stage drug development company, which develops Nicotinamide adenine dinucleotide (NAD+) cellular protection mechanisms focusing on mitochondrial diseases. The company also offers a solid oral dosage formulation of MIB-626. NAD+ key therapeutic arears various aging and numerous diseases such as mitochondrial dysfunction, inflammation and other related diseases. The company also focuses on isotopic labeling, molecular biology and nucleoside chemistry activities and is also carrying out phase 2 trials at various hospitals. Metro International Biotech is headquartered in Birmingham, Michigan, the US
For a complete picture of MIB-626’s drug-specific PTSR and LoA scores, buy the report here.